Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on June 8, 2018. The filing addresses a material modification to the rights of security holders and amendments to the Company's Articles of Incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance and capital structure changes.
Material Changes
- Reverse Stock Split: The Company effected a one-for-ten (1:10) reverse stock split of its common stock, effective as of 4:10 p.m. Eastern Time on June 8, 2018.
- Share Count Reduction: The number of outstanding shares was reduced from approximately 115.9 million to approximately 11.6 million.
- Listing Compliance: The split was implemented to regain compliance with Exchange listing standards after receiving notice on January 4, 2018, regarding the Company's low share price. Compliance was required by July 5, 2018.
- Trading Details: Trading on a reverse split-adjusted basis was anticipated to begin on June 11, 2018. The trading symbol remains "IBIO," and the new CUSIP number is 451033 203.
- Fractional Shares: No fractional shares were issued; holders entitled to fractional shares received cash payments in lieu thereof.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance or management commentary on future operations. The primary risk addressed was the potential delisting from the Exchange due to low share price, which the reverse stock split was designed to mitigate. The filing notes that the split applies to outstanding stock options but does not affect the par value or the total number of authorized shares.
Investor Verification Checklist
- Verify the new CUSIP number (451033 203) for trading and record-keeping purposes.
- Confirm the adjusted share count in brokerage accounts following the June 11, 2018 trading resumption.
- Check for cash payments received in lieu of fractional shares if applicable.
- Review the impact of the 1:10 split on the exercise price and number of shares for any outstanding stock options.